CNB Bank Sells 240 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

CNB Bank decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.9% during the 4th quarter, Holdings Channel reports. The firm owned 2,462 shares of the medical research company’s stock after selling 240 shares during the quarter. CNB Bank’s holdings in Charles River Laboratories International were worth $454,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in CRL. Virtu Financial LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter valued at $601,000. JPMorgan Chase & Co. grew its holdings in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares during the last quarter. State Street Corp increased its stake in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after buying an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new position in Charles River Laboratories International during the 3rd quarter worth about $966,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 0.4 %

CRL opened at $166.49 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $160.85 and a twelve month high of $275.00. The firm has a market cap of $8.51 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm’s fifty day moving average is $191.67 and its two-hundred day moving average is $198.72.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the business posted $2.72 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on CRL. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. William Blair restated an “outperform” rating on shares of Charles River Laboratories International in a research report on Tuesday. Redburn Atlantic assumed coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. UBS Group reissued a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).